Valerio Therapeutics (C4X) Stock Statistics & Valuation Metrics
Total Valuation
Valerio Therapeutics has a market cap or net worth of EUR 275.78M. The enterprise value is EUR 77.01T.
- Market Cap
- EUR 275.78M
- Enterprise Value
- EUR 77.01T
Share Statistics
Valerio Therapeutics has 587,615,970 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 587,615,970
- Owned by Insiders
- ―
- Owned by Institutions
- ―
Financial Efficiency
Valerio Therapeutics’s return on equity (ROE) is -2.36 and return on invested capital (ROIC) is -5.50%.
- Return on Equity (ROE)
- -2.36
- Return on Assets (ROA)
- -0.32
- Return on Invested Capital (ROIC)
- -5.50%
- Return on Capital Employed (ROCE)
- -0.06
- Revenue Per Employee
- 62.76K
- Profits Per Employee
- -119.46K
- Employee Count
- 41
- Asset Turnover
- 0.17
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Valerio Therapeutics is -10.75. Valerio Therapeutics’s PEG ratio is 1.27.
- PE Ratio
- -10.75
- PS Ratio
- 48.84
- PB Ratio
- -324.63
- Price to FCF
- 89.03
- Price to Operating Cash Flow
- 15.90
- PEG Ratio
- 1.27
Income Statement
In the last 12 months, Valerio Therapeutics had revenue of 2.57M and earned -4.90M in profits. Earnings per share was -0.03.
- Revenue
- 2.57M
- Gross Profit
- 1.73M
- Operating Income
- -550.00K
- Pretax Income
- -4.64M
- Net Income
- -4.90M
- EBITDA
- 542.00K
- Earnings Per Share (EPS)
- -0.03
Cash Flow
In the last 12 months, operating cash flow was 4.76M and capital expenditures -1.71M, giving a free cash flow of 3.04M billion.
- Operating Cash Flow
- 4.76M
- Free Cash Flow
- 3.04M
- Free Cash Flow per Share
- 0.02
Dividends & Yields
Valerio Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- 1.12%
- Earnings Yield
- -9.32%
Stock Price Statistics
- Beta
- 0.62
- 52-Week Price Change
- 204.64%
- 50-Day Moving Average
- 0.52
- 200-Day Moving Average
- 0.35
- Relative Strength Index (RSI)
- 52.87
- Average Volume (3m)
- 12.14K
Important Dates
Valerio Therapeutics upcoming earnings date is ―, TBA (Not Confirmed).
- Last Earnings Date
- Oct 29, 2025
- Next Earnings Date
- ―
- Ex-Dividend Date
- ―
Financial Position
Valerio Therapeutics as a current ratio of 0.76, with Debt / Equity ratio of 366.60%
- Current Ratio
- 0.76
- Quick Ratio
- 0.76
- Debt to Market Cap
- 0.34
- Net Debt to EBITDA
- 12.09
- Interest Coverage Ratio
- -1.96
Taxes
In the past 12 months, Valerio Therapeutics has paid 261.00K in taxes.
- Income Tax
- 261.00K
- Effective Tax Rate
- -0.06
Enterprise Valuation
Valerio Therapeutics EV to EBITDA ratio is -216.67, with an EV/FCF ratio of 93.03.
- EV to Sales
- 51.03
- EV to EBITDA
- -216.67
- EV to Free Cash Flow
- 93.03
- EV to Operating Cash Flow
- 59.52
Balance Sheet
Valerio Therapeutics has EUR 656.00K in cash and marketable securities with EUR 12.84M in debt, giving a net cash position of -EUR 12.19M billion.
- Cash & Marketable Securities
- EUR 656.00K
- Total Debt
- EUR 12.84M
- Net Cash
- -EUR 12.19M
- Net Cash Per Share
- -EUR 0.02
- Tangible Book Value Per Share
- -EUR 0.05
Margins
Gross margin is 62.84%, with operating margin of -16.67%, and net profit margin of -127.07%.
- Gross Margin
- 62.84%
- Operating Margin
- -16.67%
- Pretax Margin
- -119.55%
- Net Profit Margin
- -127.07%
- EBITDA Margin
- -23.55%
- EBIT Margin
- -117.39%
Analyst Forecast
The average price target for Valerio Therapeutics is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- 203.22%
- EPS Growth Forecast
- 62.89%
